

National Board of Examinations

Question Paper Name :	DrNB CLINICAL HAEMATOLOGY Paper2
Subject Name :	DrNB CLINICAL HAEMATOLOGY Paper2
Creation Date :	2025-01-19 09:52:24
Duration :	180
Total Marks :	100
Display Marks:	No
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB CLINICAL HAEMATOLOGY Paper2

Group Number :	1
Group Id :	3271873443
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100

DrNB CLINICAL HAEMATOLOGY Paper2

Section Id :	3271873446
Section Number :	1
Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions :	10
Number of Questions to be attempted :	10
Section Marks :	100
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271873450
Question Shuffling Allowed :	No

Question Number : 1 Question Id : 32718736704 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) List the diagnostic criteria of VEXAS syndrome. [4]
- b) Briefly describe the pathophysiology of VEXAS syndrome. [3]
- c) Discuss briefly the best current therapy of VEXAS syndrome. [3]

Question Number : 2 Question Id : 32718736705 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Describe the pathophysiology of paraproteinemic neuropathy. [4]
- b) Discuss the clinical manifestations commonly seen in paraproteinemic neuropathy. [3]
- c) Enumerate the conditions which are frequently associated with paraproteinemic neuropathy. [3]

Question Number : 3 Question Id : 32718736706 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Compare between MGUS and smoldering myeloma. [4]
- b) Discuss the monitoring strategy in patients with MGUS and smoldering myeloma. [3]
- c) What are the indications for therapy in both conditions - MGUS and smoldering myeloma? [3]

Question Number : 4 Question Id : 32718736707 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) What steps can be taken by different stake holders to prevent wrong blood transfusion? [4]
- b) What is delayed hemolytic blood transfusion reaction? [3]
- c) What are the common causes of delayed hemolytic transfusion reaction? [3]

Question Number : 5 Question Id : 32718736708 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) A patient with a mechanical heart valve on vitamin K antagonist therapy requires surgery. How will you do bridging anticoagulation in this patient? [4]
- b) If the patient is on Rivaroxaban or Apixaban – what differences in halting or changing anti-coagulation are needed? [3]

c) What are the current recommendations of anti-coagulation therapy for a man diagnosed with antiphospholipid syndrome (APLA)? [3]

Question Number : 6 Question Id : 32718736709 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Briefly discuss the diagnostic criteria of autoimmune lymphoproliferative syndrome (ALPS). [3]
- b) What are the clinical manifestations of ALPS? [3]
- c) How will you treat a child with ALPS? [4]

Question Number : 7 Question Id : 32718736710 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) What changes to the previous group diffuse large B-cell lymphoma (DLBCL) have been made in the revised World Health Organization (WHO) classification? [4]
- b) What are the types of 'DLBCL, not otherwise specified (NOS)? [3]
- c) Briefly discuss results of the POLARIX trial. [3]

Question Number : 8 Question Id : 32718736711 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Inotuzumab ozogamicin is now approved in pediatric patients. Discuss its mechanism of action and indications. [4]
- b) What are the major adverse effects of inotuzumab ozogamicin? [3]
- c) Discuss the dose of inotuzumab ozogamicin, and how to use this drug before transplant. [3]

Question Number : 9 Question Id : 32718736712 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Briefly discuss about systemic mastocytosis and its staging. [4]
- b) Discuss the implications of KIT(D816V) mutation in systemic mastocytosis. [3]
- c) Discuss the treatment options for systemic mastocytosis. [3]

Question Number : 10 Question Id : 32718736713 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Enumerate the conditions under iron refractory iron deficiency anemia (IRIDA). [4]
- b) What is your approach to diagnosis of a patient suspected as having IRIDA? [3]
- c) How do patients with TMPRSS6 (transmembrane serine protease 6) gene mutation present? [3]